Birgit H. Amann, MD

ADHD experts share their final thoughts on the treatment and management of ADHD.

Drs Feld, Cutler, Mao, and Amann discuss unmet needs in the management of ADHD.

ADHD experts discuss strategies for improving access to ADHD medications for their patients.

ADHD experts discuss novel treatments and unmet needs in pediatric and adult patients.

Drs Cerulli and Cutler discuss the data and pharmacological properties of amphetamine XR oral tablets.

Panelists discuss the use of amphetamine XR oral tablets in their practice and for which patients they’re using them.

Birgit H. Amann, MD, PLLC, discusses 2 recently approved treatment options for ADHD: amphetamine XR oral tablets and viloxazine.

Panelists discuss the importance of choosing treatments that are individualized to their patients.

Psychiatrists share their approach to choosing between different ADHD medications and formulations.

Dr Feld highlights several formulations that are available to treat ADHD.

Dr Cutler shares treatment options for ADHD.

Dr Amann and other experts discuss importance of carefully weighing patient and parent expectations and goals when choosing treatment.

Drs Cerulli and Cutler discuss factors guiding treatment selection in ADHD.

ADHD experts discuss their approaches to management of ADHD in patients with comorbidities.

Psychiatrists share how they have incorporated telemedicine in the management of ADHD in their clinics.

Panelists share clinical burden of ADHD and how it impacts pediatric, adolescent and adult populations.

ADHD experts discuss presentation and underdiagnosis of ADHD in adults.

Drs Cerulli, Feld, Cutler, Mao, and Amann discuss prevalence and presentation of ADHD in pediatric, adolescent and adult populations.

Drs Rakesh Jain, Greg Mattingly, David W. Goodman, Birgit H. Amann, and Theresa R. Cerulli, discuss emerging agents in the pipeline for the management of pediatric and adult ADHD.

David W. Goodman, MD, leads a discussion on the use of viloxazine for the treatment of adults with ADHD.

Birgit H. Amann, MD, and Greg Mattingly, MD, share strategies for mitigating adverse events with viloxazine in ADHD and its effect on metabolism of drugs.

Key opinion leaders in the management of ADHD comment on where they anticipate using viloxazine and other nonstimulants in the ADHD treatment landscape.

Greg Mattingly, MD, and David W. Goodman, MD, discuss the recent approval of viloxazine in children and its clinical profile in the pediatric and adult populations in ADHD.

Birgit H. Amann, MD; Rakesh Jain, MD, MPH; Theresa R. Cerulli, MD; and David W. Goodman, MD, share unmet needs and risks in the treatment of adult ADHD.

Dr David W. Goodman reviews the efficacy and tolerability of different classes of medications for the management of ADHD.

Rakesh Jain, MD, MPH, explores the role of an integrative treatment approach in regard to nonpharmacological treatment for the management of adult ADHD.

Rakesh Jain, MD, MPH, leads a discussion on factors that guide treatment selection for adult patients with ADHD.

Experts in ADHD discuss the benefits and challenges of telehealth on the diagnosis and management of adult ADHD.

Birgit H. Amann, MD, and Greg Mattingly, MD, review patient and provider goals of treatment and provide insight on evaluating response to treatment for ADHD.

Greg Mattingly, MD; David W. Goodman, MD; Birgit H. Amann, MD; and Theresa R. Cerulli, MD, evaluate the role of pediatric ADHD guidelines and common misconceptions in the diagnosis and treatment of ADHD.